Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEO Shuffle: Daiichi Sankyo Appoints Second New Ranbaxy Leader In Less Than 15 Months

This article was originally published in The Pink Sheet Daily

Executive Summary

The Indian drug maker will see a changing of the guard, as chief executive Atul Sobti steps down and hands over the reins to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business.

You may also be interested in...



Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor

MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim

Corrective Actions "Inadequate," U.S. FDA Warns Ranbaxy; Threatens Seizure And Injunction

MUMBAI - Ranbaxy's four-year-long tangle with U.S. FDA over the Indian firm's troubled manufacturing sites took one more serious turn as the world's most powerful regulatory agency fired another salvo saying: "It is apparent that Ranbaxy's attempts to make global corrections after past regulatory actions by the FDA have been inadequate.

"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)

Japan's third-largest drug maker, Daiichi Sankyo, acquired a 64- percent stake in India's most internationally known pharmaceutical brand - Ranbaxy - last June. The deal between an emerging innovator and an established generics drug maker surprised many, but was seen as a transformational one with a goal to expand reach and enhance cost efficiencies. Daiichi Sankyo was criticized later as concerns surfaced regarding Ranbaxy's manufacturing standards at two of its U.S.FDA-approved sites in India. After a complete management overhaul that saw Ranbaxy's promoter exiting the company, Daiichi Sankyo made Atul Sobti the CEO and managing director. In arguably the most in-depth interview after taking over the reins of Ranbaxy, Sobti, who has worked previously with companies like Hero Honda, opened up to PharmAsia News' India bureau on issues spanning U.S. FDA's actions to rebuilding Ranbaxy's reputation and opportunities in Europe, Africa, Japan and India.

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel